1Beardsley DS. Pathophysiology of immune thrombocytopenic purpura. Blood Rev, 2002, 16: 13-14.
2Lambotte O, Gelu-Simeon M, Maigne G, et al. Pegylated interf:'on alpha-2a-associated life-threatening Evans' syndrome in a patient with chronic hepatitis C. J Infect, 2005, 51: e113-115.
3Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B (2010 version). Chin J V'Lral Dis, 2011, 1: 9-23. (in Chinese).
4Tseng TC, Liu C J, Yang HC, et al. Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load. Hepatology, 2012, 55: 68-76.
5Tseng TC, Liu CJ, Su TH, et al. Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters. Gastroenterology, 2011, 14:517-525.
2Jakacki R I, Dombi E, Potter D M, et al. Phase I trial of pegylated interferon- α - 2b in young pa- tients with plexiform neurofibromas[J]. Neurology, 2011, 76(3): 265 - 272.
3Hao J, Jin W, Li X, et al. Inhibition of alpha inter- feron (IFN- α) - induced microRNA - 122 negative- ly affects the.anti- hepatitis B virus efficiency of IFN -α [J]. Journal of Virology, 2013, 87(1): 137- 147.
4Mauracher E. Low dose interferon alfa- 2b for chro- nic hepatitis B in Asian countries[J]. Gut, 1993, 34 (2 Suppl) :S99 - 100.
